Structure via PubChem · Public domain (PubChem)
lopinavir
Sign in to saveAlso known as LPV
Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir (lopinavir/ritonavir).
Chemical data
- Formula
- C37H48N4O5
- Molecular weight
- 628.8 g/mol
- IUPAC name
- (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
- SMILES
- CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O
- InChIKey
- KJHKTHWMRKYKJE-SUGCFTRWSA-N
- XLogP
- 5.9
- Polar surface area
- 120 Ų
- H-bond donors
- 4
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Research
4,600 papers- Lopinavir-ritonavir for COVID-19: A living systematic review.Medwave · 2020
- Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2021
- Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.European review for medical and pharmacological sciences · 2020
- Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications.Cardiovascular drugs and therapy · 2021
- Lopinavir.Drugs · 2000
via PubMed
Wikidata facts
- Mass
- 628.362
Show 4 more facts
- chemical formula
- C₃₇H₄₈N₄O₅
- canonical SMILES
- CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O
- isomeric SMILES
- CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O
- Commons category
- Lopinavir
via Wikidata · CC0
~3 min read
Article
5 sectionsContents
- Side effects
- Pharmacology
- Research
- Synthesis
- References
Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir (lopinavir/ritonavir).
It was patented in 1995 and approved for medical use in 2000. Considered now as second-line therapy in the West, it is still prescribed in LMIC, especially among children living with HIV. Lopinavir and ritonavir can be taken as a tablet or an oral solution, a preferred option in children. In the early stages of COVID-19 pandemics, lopinavir was repurposed against the SARS-CoV-2 virus in the hope of disturbing its protease activity.